ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 555

Three Year Outcomes of Patients with Elderly-Onset Rheumatoid Arthritis Treated with a Therapeutic Strategy Targeting Low Disease Activity, and Impact of Adverse Events on Physical Function

Takahiko Sugihara1, Tatsuro Ishizaki2, Hiroyuki Baba3, Takumi Matsumoto3, Shoko Iga1, Takeshi Kusuda1, Marina Tsuchida1, Mari Kamiya3, Yoji Komiya3, Fumio Hirano4, Tadashi Hosoya3, Nobuyuki Miyasaka3 and Masayoshi Harigai5, 1Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 2Human Care Research Team, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, 3Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 4Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, 5Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Elderly, physical function, rheumatoid arthritis (RA) and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The aim of this study was to evaluate three year outcomes of patients with elderly-onset RA (EORA) who were treated with a therapeutic strategy targeting low disease activity (LDA), and clinical factors associated with physical dysfunction in patients who achieved LDA.

Methods:

Data of 197 MTX-naïve EORA (mean age 74.9) from a prospective, monocentric registry were analyzed. Treatment was adjusted targeting LDA defined by DAS28-ESR or simplified disease activity index (SDAI). Treatment was initiated with non-biologic DMARDs (nbDMARDs), followed by biologic DMARDs such as TNF inhibitors, tocilizumab, or abatacept. Primary outcomes were obtained from SDAI and the HAQ disability index (HAQ-DI). Serious adverse events (SAEs) during three years of observational period were assessed at all visits. Associated factors of physical dysfunction (HAQ-DI >0.5) in patients who achieved SDAI-LDA at week 156 or at dropout were examined using multivariate logistic regression models.

Results:

MTX was administered in 167 (85%) of the 197 patients, and dose-dependent adverse drug reactions were observed in 100 patients, and 158 patients received mean 8.5 mg/week of MTX at week 24, and 35% of them received a biologic DMARD with or without MTX at week 52, 36% at week 104, and 33% at week 156. Median dose of 3.5mg/day of prednisolone (PSL) were administered with DMARDs in 17% of the patients at week 156. Adherence to the treat-to-target (T2T) strategy was observed in 81%, 87%, 91% at week 24, 52, and 104 weeks, respectively. At week 56, 104, and 156, SDAI-LDA was achieved in 73%, 82%, and 88% by last observation carried forward analysis, SDAI-remission in 36%, 50%, and 56%, and HAQ-DI ≤0.5 in 68%, 71%, and 72%, respectively. Clinically relevant radiological progression (CRRP: Δ modified total sharp score [mTSS] /year >the smallest detectable change [2.1]) was observed in 28% at week 52. Infection requiring hospitalization occurred in 31 patients during the observational period, extra-articular manifestations in 13, ischemic heart disease in 9, malignancy in 11, and bone fracture in 20. Twenty-nine (15%) of the 197 patients dropped from the study for aging (dementia or sarcopenia) in 11, patient decision in 6, exacerbation of interstitial lung disease in 5, infection in 4, malignancy in 2, and sudden death in 1, and 18 of the 29 patients achieved LDA at dropout. HAQ-DI ≤0.5 was not achieved in 46 of the 173 patients who achieved LDA at week 156 or at dropout. Multivariate analysis showed older age (odds ratio (OR) 1.15, 95% confidence interval (CI) 1.07-1.23), SAEs occurred during the observational period (OR 3.96, 95%CI 1.76-8.92), and higher SDAI (OR 1.16, 95%CI 1.02-1.33) were significantly associated with risk of non-achievement of HAQ-DI ≤0.5 in patients who achieved SDAI-LDA. Comorbidities at baseline, mTSS at baseline, and CRRP at week 52 were not significant. Infection requiring hospitalization, ischemic heart disease, and bone fracture were significant among the SAEs.

Conclusion:

The patients with EORA can achieve clinical remission and normal physical function by therapeutic strategy targeting LDA. SAEs under T2T strategy of EORA have great impact on physical dysfunction in patients who achieved treatment goals.


Disclosure: T. Sugihara, Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi-Tanabe Pharma Co., Astellas Pharma Inc., Bristol Myers Squibb K.K., Pfizer Inc. and Abbvie Japan Co., Ltd., 5; T. Ishizaki, None; H. Baba, None; T. Matsumoto, None; S. Iga, None; T. Kusuda, None; M. Tsuchida, None; M. Kamiya, None; Y. Komiya, None; F. Hirano, Chugai Pharmaceutical Co., Ltd.; Ono Pharmaceuticals; Mitsubishi Tanabe Pharma Co.; UCB Japan; CSL Behring; Towa Pharmaceutical Co., Ltd.; Abbvie Japan Co., Ltd.; Japan Blood Products Organization; Ayumi Pharmaceutical Co.; Sumitomo Dainippon Pharmaand, a, 2, 5; T. Hosoya, None; N. Miyasaka, None; M. Harigai, Chugai Pharmaceutical Co. Ltd., Teijin Pharma Co. Ltd., 2, 5.

To cite this abstract in AMA style:

Sugihara T, Ishizaki T, Baba H, Matsumoto T, Iga S, Kusuda T, Tsuchida M, Kamiya M, Komiya Y, Hirano F, Hosoya T, Miyasaka N, Harigai M. Three Year Outcomes of Patients with Elderly-Onset Rheumatoid Arthritis Treated with a Therapeutic Strategy Targeting Low Disease Activity, and Impact of Adverse Events on Physical Function [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/three-year-outcomes-of-patients-with-elderly-onset-rheumatoid-arthritis-treated-with-a-therapeutic-strategy-targeting-low-disease-activity-and-impact-of-adverse-events-on-physical-function/. Accessed March 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/three-year-outcomes-of-patients-with-elderly-onset-rheumatoid-arthritis-treated-with-a-therapeutic-strategy-targeting-low-disease-activity-and-impact-of-adverse-events-on-physical-function/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences